Compare Abeona Therapeutics Inc (ABEO) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Marathon Petroleum Corp — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Marathon Petroleum Corp trades at $335.6 (market cap $89.95B). The key difference: Marathon Petroleum Corp is far larger — about 212× Abeona Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 1.25% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MPC | |
|---|---|---|
Market Cap | $424.33M | $89.95B |
Sector | Health | Energy |
52-Week High | $7.45 | $336.42 |
52-Week Low | $4.17 | $159.11 |
Enterprise Value | $279.23M | $116.48B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Marathon Petroleum (MPC) trades at $298.20, down 0.35% with a bearish technical signal despite strong fundamental performance. The stock shows exceptional earnings momentum with three consecutive quarterly beats, including a massive Q2 2026 EPS of $17.73 versus $14.27 expected. Valuation remains attractive with P/E of 10.34 and EV/EBITDA of 6.26, while maintaining robust profitability with 47.9% ROE.
MPC presents a compelling investment case with strong analyst support (76% buy ratings) and $330.70 price target upside. However, declining revenue trends from $177.5B in 2022 to $132.7B in 2025 and rising debt-to-asset ratio to 42.59% pose fundamental concerns. Technical weakness near pivot point resistance at $297 requires monitoring despite positive refining margin outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
